Daniel Estes
General Partner at Frazier Life Sciences
Daniel Estes
General Partner at Frazier Life Sciences
San Diego, California
Overview
Work Experience
General Partner
2011 - Current
Healthcare-focused investment firm founded in 1991, with our Frazier Life Sciences (FLS) team focused on investing in and building companies developing novel therapeutics. Investing out of FLS XI, a $987M venture fund raised in 2022, and FLS PF, a >$800M evergreen vehicle for publics and crossover investments. * Current Boards: Hummingbird Bioscience (Singapore), Radionetics, Hawkeye Therapeutics, Sudo Biosciences, Inipharm * Prior Boards: Arcutis Biotherapeutics (NASDAQ: ARQT), Lengo Therapeutics (acquired by Blueprint), Tarsus (observer, NASDAQ: TARS), Semnur Pharmaceuticals (acquired by Scilex), Sierra Oncology (NASDAQ: SRRA, acquired by GSK) * Selected Other Deals: Acerta (sold to AZ), Vaxcyte (NASDAQ: PCVX), PreCision Dermatology (sold to Valeant), Tobira (TBRA, sold to Allergan), Rempex (sold to The Medicines Company), Ignyta (sold to Roche), ARMO (sold to Lilly), Iovance (NASDAQ: IOVA), Translate Bio (NASDAQ: TBIO)
Biotechnology Consultant
2008 - 2011
Focus on pharmaceuticals and biotechnology, specifically R&D and corporate strategy